Updated:
aTYR Pharma
aTYR Pharma, led by CEO Sanjay Shukla, is a San Diego biotech advancing efzofitimod, a tRNA synthetase-derived therapy for sarcoidosis.
aTYR Pharma
Founded in 2005 by Paul Schimmel, a molecular biologist whose work at The Scripps Research Institute established the extracellular functions of tRNA synthetases, aTYR Pharma translates decades of foundational research into therapeutic candidates. The intellectual property is rooted in Schimmel’s discovery that these ancient proteins, previously understood only for their intracellular role in translation, also serve as extracellular signaling molecules. The company’s origin is scientific, not capital-deployment, making it an operating biotech rather than a family office or fund manager. The company’s strategy centers on efzofitimod (formerly ATYR1923), a first-in-class immunomodulator that selectively binds to neuropilin-2 (NRP2) to reduce inflammatory myeloid cell activity. Efzofitimod completed a Phase 3 registrational study (EFZO-FIT) in pulmonary sarcoidosis in Q3 2024, with the firm reporting positive topline results showing a statistically significant reduction in oral corticosteroid use versus placebo. Beyond sarcoidosis, aTYR has explored interstitial lung disease as a follow-on indication. The burn rate and clinical milestones define its deployment profile, not AUM, with the firm funding operations through public equity raises on Nasdaq. Sanjay Shukla, President and CEO since 2020, steers a lean, research-driven organization headquartered in San Diego. The firm reported cash and investments of roughly $105 million as of September 2024, funding operations into 2026. In Q1 2025, the firm announced plans to submit a Biologics License Application to the FDA for efzofitimod and enter into a licensing agreement with Kyorin Pharmaceutical for development and commercialization of the candidate in Japan, providing a non-dilutive cash injection. The team remains concentrated in Southern California, with no significant satellite offices. What structurally sets aTYR apart from large pharma is its monomaniacal focus on the tRNA synthetase biology pioneered by its founder. The firm is built entirely around a single, proprietary biological insight — the immunomodulatory function of a splice variant of histidyl-tRNA synthetase — rather than assembling a portfolio of in-licensed assets. This narrow aperture creates binary clinical risk but also a clear scientific identity for potential partners like Kyorin to evaluate.
General information
Firm type
Asset Manager
Year founded
2005
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Sanjay S. Shukla
President and Chief Executive Officer
Sector focus
Frequently asked questions
Who founded aTYR Pharma and what is the core scientific premise?
Paul Schimmel, a prominent molecular biologist from The Scripps Research Institute, founded the company in 2005. His research demonstrated that tRNA synthetases — proteins historically known for their role in protein synthesis — also function outside the cell as signaling molecules that regulate inflammation and immune response. aTYR’s entire pipeline derives from this discovery.
What is the lead drug candidate and its clinical status?
The lead candidate is efzofitimod, an immunomodulator targeting the neuropilin-2 receptor to reduce inflammatory myeloid cell activity. It completed a Phase 3 registrational trial (EFZO-FIT) for pulmonary sarcoidosis in 2024, reporting positive topline results for the primary endpoint of corticosteroid reduction. The firm expects to file a Biologics License Application with the FDA by mid-2025.
Does aTYR Pharma generate revenue or operate as an investment vehicle?
aTYR Pharma is a clinical-stage biotherapeutics company with no commercial products on the market yet; it does not generate material product revenue. It is not a family office, asset manager, or investment vehicle. The firm funds operations through equity offerings on Nasdaq and, more recently, through a regional licensing deal with Kyorin Pharmaceutical for the Japanese market.
Which geographies does aTYR Pharma target for commercialization?
aTYR retained global rights to efzofitimod but signed a licensing agreement with Kyorin Pharmaceutical in early 2025 for development and commercialization specifically in Japan. The company plans to commercialize the drug in the United States and Europe directly or through further regional partnerships, starting with the FDA submission for pulmonary sarcoidosis.
What is aTYR Pharma's current financial position?
As of its Q3 2024 filing, aTYR reported roughly $105 million in cash and cash equivalents. The licensing deal with Kyorin provides an additional non-dilutive upfront payment. Management expects that current funds, combined with anticipated milestones, are sufficient to sustain core operations into 2026 as it prepares for a potential first commercial launch.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: